Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA)’s stock price has plunge by 1.01relation to previous closing price of 16.39. Nevertheless, the company has seen a 6.26% surge in its stock price over the last five trading sessions. benzinga.com reported 2025-05-05 that The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. TEVA and Alvotech’s ALVO Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Johnson & Johnson’s JNJ Stelara (ustekinumab).
Is It Worth Investing in Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Right Now?
Additionally, the 36-month beta value for TEVA is 0.59. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for TEVA is 1.15B and currently, short sellers hold a 2.65% ratio of that float. The average trading volume of TEVA on May 06, 2025 was 11.96M shares.
TEVA’s Market Performance
TEVA’s stock has seen a 6.26% increase for the week, with a 19.96% rise in the past month and a -2.96% fall in the past quarter. The volatility ratio for the week is 3.72%, and the volatility levels for the past 30 days are at 5.13% for Teva- Pharmaceutical Industries Ltd. ADR The simple moving average for the past 20 days is 14.03% for TEVA’s stock, with a -5.50% simple moving average for the past 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Argus repeating the rating for TEVA by listing it as a “Buy.” The predicted price for TEVA in the upcoming period, according to Argus is $20 based on the research report published on July 10, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $14. The rating they have provided for TEVA stocks is “Neutral” according to the report published on March 08th, 2024.
Piper Sandler gave a rating of “Overweight” to TEVA, setting the target price at $19 in the report published on February 12th of the previous year.
TEVA Trading at 8.43% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.39% of loss for the given period.
Volatility was left at 5.13%, however, over the last 30 days, the volatility rate increased by 3.72%, as shares surge +18.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.16% lower at present.
During the last 5 trading sessions, TEVA rose by +6.45%, which changed the moving average for the period of 200-days by +1.50% in comparison to the 20-day moving average, which settled at $14.52. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw -24.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Daniell Richard, who sale 70,961 shares at the price of $15.91 back on Mar 05 ’25. After this action, Daniell Richard now owns 48,384 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $1,128,642 using the latest closing price.
Hughes Eric A, the See “Remarks” of Teva- Pharmaceutical Industries Ltd. ADR, sale 15,174 shares at $15.73 during a trade that took place back on Mar 04 ’25, which means that Hughes Eric A is holding 8,077 shares at $238,757 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.49 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.1. The total capital return value is set at -0.01. Equity return is now at value -25.44, with -3.96 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 3.36. The interest coverage ratio of the stock is -0.3.
Currently, EBITDA for the company is 716.0 million with net debt to EBITDA at 19.02. When we switch over and look at the enterprise to sales, we see a ratio of 2.06. The receivables turnover for the company is 5.41for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.98.
Conclusion
In conclusion, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
